Eric Sirota
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Eric Sirota has a total of 362 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra C. Sun
Process Research and Development, Merck & Co., Inc., Rahway, NJ, USA
4 shared publications - David A. Thaisrivongs
Department of Process Research and Development
4 shared publications - Kai-Jiong Xiao
Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
4 shared publications - Lorenzo Codan
Department of Process Research and Development, MSD Werthenstein BioPharma GmbH, Industrie Nord 1, 6105 Schachen, Switzerland
4 shared publications Yongqian Zhang
Merck & Co., Inc.
4 shared publicationsAnthony Diaz-Santana
Merck & Co., Inc, Rahway, New Jersey 07065, United States
3 shared publications
Latest Publications
- 31 August 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 30 (9) , 2540-2548
Synthesis of N -Linked Amino-Hexyl Fluorotryptophan for Enlicitide, Part 2: Process Improvements toward Commercial Manufacture
Herein, we report the development of a robust manufacturing process for N-linked amino-hexyl fluorotryptophan 3, a key building block for enlicitide decanoate (MK-0616), which is an orally bioavailable inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). Targeted process development enabled safe operation of the Delépine reaction, increased yields for the hexamine hydrolysis and enzymatic tryptophan synthesis, and established a robust and selective N-alkylation of 5-fluorotryptophan. Collectively, these improvements afforded the target product with high yield, >98.5% purity, and favorable physical properties suitable for commercial manufacture.
- 31 August 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 30 (9) , 2540-2548
Synthesis of N -Linked Amino-Hexyl Fluorotryptophan for Enlicitide, Part 2: Process Improvements toward Commercial Manufacture
Herein, we report the development of a robust manufacturing process for N-linked amino-hexyl fluorotryptophan 3, a key building block for enlicitide decanoate (MK-0616), which is an orally bioavailable inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). Targeted process development enabled safe operation of the Delépine reaction, increased yields for the hexamine hydrolysis and enzymatic tryptophan synthesis, and established a robust and selective N-alkylation of 5-fluorotryptophan. Collectively, these improvements afforded the target product with high yield, >98.5% purity, and favorable physical properties suitable for commercial manufacture.
- 19 August 2026
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 28 (35) , 11053-11057
Stereoselective Synthesis of MK-8527 Enabled by a Dynamic Kinetic Resolution Mitsunobu Glycosylation
A practical and asymmetric synthesis of potent anti-HIV nucleoside MK-8527 is described. The key discoveries are a novel stereoselective dynamic kinetic resolution (DKR) Mitsunobu glycosylation and selective amination of the resulting 2,6-dichloro nucleoside. The new route was successfully demonstrated on the kilogram scale and provided isolated MK-8527 with more than 99% HPLC purity through crystallization.
- 19 August 2026
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 28 (35) , 11053-11057
Stereoselective Synthesis of MK-8527 Enabled by a Dynamic Kinetic Resolution Mitsunobu Glycosylation
A practical and asymmetric synthesis of potent anti-HIV nucleoside MK-8527 is described. The key discoveries are a novel stereoselective dynamic kinetic resolution (DKR) Mitsunobu glycosylation and selective amination of the resulting 2,6-dichloro nucleoside. The new route was successfully demonstrated on the kilogram scale and provided isolated MK-8527 with more than 99% HPLC purity through crystallization.
- 4 June 2026
- Published by American Chemical Society (ACS) in Crystal Growth & Design
- Vol. 26 (12) , 4478-4489
Screening Crystallization Solvents for Yield and Purity Upgrade Using High-Throughput Solubility
Crystallization is ubiquitous as a method to purify chemical intermediates and drug substances across the pharmaceutical industry. A significant challenge in the development of a crystallization process is the identification of an optimal solvent system that provides high crystallization yield and purity. In this work, we describe a screening approach leveraging high-throughput experimentation and modeling to estimate impurity rejection and crystallization yield across a range of solvents and antisolvents. Models to compute impurity rejection were informed on the basis of the experimentally determined impurity retention mechanisms. Despite greater error associated with predicting yield and purity upgrade for solid solutions as compared to systems with immiscible impurities, our proposed method accurately estimated the yield (R2 = 0.88) and purity (R2 = 0.73) achieved by crystallizations in a variety of solvents and antisolvents for three industrially relevant compounds. These results demonstrate a practical workflow where high-throughput solubility can inform the crystallization process design space, offering a data-rich approach for crystallization development across the pharmaceutical industry.
- 4 June 2026
- Published by American Chemical Society (ACS) in Crystal Growth & Design
- Vol. 26 (12) , 4478-4489
Screening Crystallization Solvents for Yield and Purity Upgrade Using High-Throughput Solubility
Crystallization is ubiquitous as a method to purify chemical intermediates and drug substances across the pharmaceutical industry. A significant challenge in the development of a crystallization process is the identification of an optimal solvent system that provides high crystallization yield and purity. In this work, we describe a screening approach leveraging high-throughput experimentation and modeling to estimate impurity rejection and crystallization yield across a range of solvents and antisolvents. Models to compute impurity rejection were informed on the basis of the experimentally determined impurity retention mechanisms. Despite greater error associated with predicting yield and purity upgrade for solid solutions as compared to systems with immiscible impurities, our proposed method accurately estimated the yield (R2 = 0.88) and purity (R2 = 0.73) achieved by crystallizations in a variety of solvents and antisolvents for three industrially relevant compounds. These results demonstrate a practical workflow where high-throughput solubility can inform the crystallization process design space, offering a data-rich approach for crystallization development across the pharmaceutical industry.
- 12 May 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (6) , 3383-3396
Controlling the Size and Shape of Monoclonal Antibody Particles through Crystallization Process Design
The crystallization of monoclonal antibodies is deemed particularly challenging due to their large size and structural flexibility. An additional challenge is represented by the tendency of mAb crystals to rapidly lose their crystallinity when removed from liquid and exposed to air or nitrogen, which complicates filtration. This study aims to develop crystallization design strategies for mAbs using the caffeine cocrystal of pembrolizumab as a model. Optimal crystallization conditions are identified by minimizing cycle times for crystallization and filtration. Metrics are introduced to rank the filtration performance of the different crystalline particle populations. This work focuses on the crystallization of caffeine cocrystal-1 of pembrolizumab, which is consistently generated upon charge of the crystallizing agent poly(ethylene glycol) 3350 (PEG) and of mediating salts, among others, dextran sodium sulfate (DSS). This study also demonstrates that seeding is feasible in the crystallization of mAbs and consistently shortens the cycle times for crystallization and improves the robustness of the process. As a proof of concept, seeded semicontinuous crystallizations are performed to enhance supersaturation control during crystallization when stringent impurity rejection and particle attribute specifications must be met. The isolation of crystalline mAb particles presents considerable challenge, and there are no documented studies that have established precedent for this aspirational goal. Finally, to avoid amorphization of the particles during isolation, a conservative approach is adopted to only partially deliquor the filter cake and to leave enough supernatant to fully submerge the filter cake to prevent air or nitrogen exposure. Assuming multiple filtration steps may be required to meet drug substance specifications, this study demonstrates that the crystal form can be retained through successive filtration and dilution/wash cycles with the supernatant composition adjusted after each filtration. This outcome demonstrates that the particles are resistant to changes in the solvent composition, such that the final product could be swapped from the matrix best suited for crystallization to a matrix more suitable for product delivery.
- 12 May 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (6) , 3383-3396
Controlling the Size and Shape of Monoclonal Antibody Particles through Crystallization Process Design
The crystallization of monoclonal antibodies is deemed particularly challenging due to their large size and structural flexibility. An additional challenge is represented by the tendency of mAb crystals to rapidly lose their crystallinity when removed from liquid and exposed to air or nitrogen, which complicates filtration. This study aims to develop crystallization design strategies for mAbs using the caffeine cocrystal of pembrolizumab as a model. Optimal crystallization conditions are identified by minimizing cycle times for crystallization and filtration. Metrics are introduced to rank the filtration performance of the different crystalline particle populations. This work focuses on the crystallization of caffeine cocrystal-1 of pembrolizumab, which is consistently generated upon charge of the crystallizing agent poly(ethylene glycol) 3350 (PEG) and of mediating salts, among others, dextran sodium sulfate (DSS). This study also demonstrates that seeding is feasible in the crystallization of mAbs and consistently shortens the cycle times for crystallization and improves the robustness of the process. As a proof of concept, seeded semicontinuous crystallizations are performed to enhance supersaturation control during crystallization when stringent impurity rejection and particle attribute specifications must be met. The isolation of crystalline mAb particles presents considerable challenge, and there are no documented studies that have established precedent for this aspirational goal. Finally, to avoid amorphization of the particles during isolation, a conservative approach is adopted to only partially deliquor the filter cake and to leave enough supernatant to fully submerge the filter cake to prevent air or nitrogen exposure. Assuming multiple filtration steps may be required to meet drug substance specifications, this study demonstrates that the crystal form can be retained through successive filtration and dilution/wash cycles with the supernatant composition adjusted after each filtration. This outcome demonstrates that the particles are resistant to changes in the solvent composition, such that the final product could be swapped from the matrix best suited for crystallization to a matrix more suitable for product delivery.
- Top Cited Papers
- 7 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 392 (6798) , 643-647
Biocatalytic cascades enable manufacture of the macrocyclic peptide enlicitide
Historically, many compelling therapeutic targets have been accessible only by injectable biologic drugs. Macrocyclic peptides, such as the proprotein convertase subtilisin/kexin type 9 inhibitor enlicitide for the treatment of atherosclerotic cardiovascular disease, are beginning to unlock these targets to orally administered therapies to enable broader patient access. We report the convergent biocatalytic assembly of enlicitide from simple building blocks enabled by a suite of engineered enzymes to catalyze selective peptide fragment formation, coupling, and macrocyclization in a protecting group–free manner. Together with efficient crystallizations that obviate the need for chromatography, this approach reduces the number of steps by greater than half compared with prior state-of-the-art methods, addressing long-standing synthetic challenges and offering a sustainable blueprint for the scalable development of complex peptide therapeutics.
- 7 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 392 (6798) , 643-647
Top Cited PapersBiocatalytic cascades enable manufacture of the macrocyclic peptide enlicitide
Historically, many compelling therapeutic targets have been accessible only by injectable biologic drugs. Macrocyclic peptides, such as the proprotein convertase subtilisin/kexin type 9 inhibitor enlicitide for the treatment of atherosclerotic cardiovascular disease, are beginning to unlock these targets to orally administered therapies to enable broader patient access. We report the convergent biocatalytic assembly of enlicitide from simple building blocks enabled by a suite of engineered enzymes to catalyze selective peptide fragment formation, coupling, and macrocyclization in a protecting group–free manner. Together with efficient crystallizations that obviate the need for chromatography, this approach reduces the number of steps by greater than half compared with prior state-of-the-art methods, addressing long-standing synthetic challenges and offering a sustainable blueprint for the scalable development of complex peptide therapeutics.
- 13 August 2025
- Published by American Chemical Society (ACS) in Crystal Growth & Design
- Vol. 25 (17) , 7216-7233
Leveraging Reactive Crystal Spherical Agglomeration to Enable a Scalable and Gelation-Free Manufacturing Process for Medium-Length Fatty Acid Sodium Salts
- 13 August 2025
- Published by American Chemical Society (ACS) in Crystal Growth & Design
- Vol. 25 (17) , 7216-7233
Leveraging Reactive Crystal Spherical Agglomeration to Enable a Scalable and Gelation-Free Manufacturing Process for Medium-Length Fatty Acid Sodium Salts
- 14 July 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (8) , 2076-2085
Biocatalytic Aerobic Oxidation for Large-Scale Production of trans-3-Hydroxy-l-Proline
- 14 July 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (8) , 2076-2085
Biocatalytic Aerobic Oxidation for Large-Scale Production of trans-3-Hydroxy-l-Proline
- 5 December 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114 (2) , 1010-1016
Attribute ranging as a coordinated strategy between drug substance and drug product to accelerate commercial process nomination
- 5 December 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114 (2) , 1010-1016
Attribute ranging as a coordinated strategy between drug substance and drug product to accelerate commercial process nomination
- 24 January 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (2) , 388-403
Concomitant Precipitation of Solid-State Miscible Product-Impurity Phases in Solution Crystallization – Part 2: Industrial Case Studies
- 24 January 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (2) , 388-403
Concomitant Precipitation of Solid-State Miscible Product-Impurity Phases in Solution Crystallization – Part 2: Industrial Case Studies